Add Yahoo as a preferred source to see more of our stories on Google. Valeant Pharmaceuticals Intl Inc (NYSE: VRX) stock spiked higher by more than 15 percent on Tuesday morning after the company ...

Troubled Valeant has been spinning its wheels over the past year trying to stage a turnaround that still seems light-years away. But now, it’s changing executive compensation, hoping to get some of ...

Image source: Taxcredits.net via Flickr. What: AfterValeant Pharmaceuticals (NYSE: VRX)reassured investors on Tuesday that it can still deliver on its previously issued full-year financial guidance, ...

Valeant Pharmaceuticals International has forged its biggest deal since a “rebirth” of the Costa Mesa drug maker slightly more than a year ago. The company last week said it plans to buy Xcel ...

(Reuters) - Valeant Pharmaceuticals International Inc (VRX.TO)(VRX.N) said on Tuesday it will change its name to Bausch Health Companies Inc as it seeks to distance itself from a series of scandals ...

Bausch Health agreed to pay the SEC $45 million to settle Valeant Pharmaceuticals (former name) accounting fraud schemes. Three former executives, former CEO Michael Pearson, CFO Howard Schiller and ...

Valeant Pharmaceuticals International is trying to sublease all or part of its Aliso Viejo headquarters just two years after the slimmed down drug maker moved its operations there from Costa Mesa. The ...

Valeant Pharmaceuticals has a new distribution deal with Walgreens, sending shares of the beleaguered Canadian drug company up sharply in morning trading. The company said Tuesday that the agreement ...

Valeant Pharmaceuticals, which fell under withering scrutiny after acquiring the rights to drugs and then drastically raising their prices, is changing its name. The Canadian company said Tuesday that ...

NEW YORK (Reuters) - Valeant Pharmaceuticals International Inc sought to reassure doctors on Monday that the company's decision to cut ties to a controversial specialty pharmacy would not disrupt ...

The board of Laval, Quebec, Canada-based Valeant Pharmaceuticals has launched a search for a new CEO to replace J. Michael Pearson, who has served as CEO since 2008. Here are seven things to know ...